Literature DB >> 8502779

Lyme disease.

R Kalish1.   

Abstract

The clinical features of Lyme disease have been well documented since its description as a distinct clinical entity in 1975. A better understanding of the diversity of Borrelia strains and species that cause the disease as well as new insights into the immunology and pathogenesis of Lyme disease help explain some of the observed variations in clinical manifestations. The diagnosis of Lyme disease may be straightforward when patients in endemic areas present with typical clinical features; however, the diagnosis should be in doubt when the clinical picture is nonspecific or atypical, or a feasible exposure history cannot be obtained. Laboratory diagnosis is primarily based on serologic techniques, but interpretation of test results can be fraught with uncertainty. Treatment with appropriate antibiotics is successful in the majority of cases of Lyme disease. However, some patients may not respond, and in these cases multiple repeated courses are usually ineffective and unwarranted. More data are needed to determine the appropriate treatment of Lyme disease during pregnancy, and the appropriate management of ixodes tick bites. A suitable arthropod vector and a competent animal reservoir host are essential for perpetuating Lyme disease in a geographic location. The intricate ecologic forces at work are well understood in certain endemic areas but are poorly defined elsewhere, particularly where the disease is sporadic or its existence is in question. Prevention of Lyme disease is best achieved through education regarding avoidance of the tick vector. A vaccine using a recombinant form of the OspA protein of B. burgdorferi has been successful in animal models. Whether an effective human vaccine can be developed remains unknown.

Entities:  

Mesh:

Year:  1993        PMID: 8502779

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  12 in total

1.  An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis.

Authors:  S Priem; M G Rittig; T Kamradt; G R Burmester; A Krause
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Predisposing factors for individuals' Lyme disease prevention practices: Connecticut, Maine, and Montana.

Authors:  J E Herrington; G L Campbell; R E Bailey; M L Cartter; M Adams; E L Frazier; T A Damrow; K F Gensheimer
Journal:  Am J Public Health       Date:  1997-12       Impact factor: 9.308

3.  Different classes of proteoglycans contribute to the attachment of Borrelia burgdorferi to cultured endothelial and brain cells.

Authors:  J M Leong; H Wang; L Magoun; J A Field; P E Morrissey; D Robbins; J B Tatro; J Coburn; N Parveen
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Integrins alpha(v)beta3 and alpha5beta1 mediate attachment of lyme disease spirochetes to human cells.

Authors:  J Coburn; L Magoun; S C Bodary; J M Leong
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 5.  A role for T cells in the pathogenesis of treatment-resistant Lyme arthritis.

Authors:  T Kamradt; A Krause; G R Burmester
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

6.  Borrelia burgdorferi, host-derived proteases, and the blood-brain barrier.

Authors:  Dennis J Grab; George Perides; J Stephen Dumler; Kee Jun Kim; Jinho Park; Yuri V Kim; Olga Nikolskaia; Kyoung Seong Choi; Monique F Stins; Kwang Sik Kim
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  Borrelia burgdorferi induces chemokines in human monocytes.

Authors:  H Sprenger; A Krause; A Kaufmann; S Priem; D Fabian; G R Burmester; D Gemsa; M G Rittig
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

8.  Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  J M Leong; D Robbins; L Rosenfeld; B Lahiri; N Parveen
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  A "minority" opinion about the diagnosis and treatment of Lyme arthritis.

Authors:  W Graninger
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

10.  Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis.

Authors:  T Kamradt; B Lengl-Janssen; A F Strauss; G Bansal; A C Steere
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.